PCT
PureCycle Technologies, Inc.
$2.92
-4.89% 2026-10-19
Industrials
PCTSPY
1W
-18.9%
1M
-49.0%
3M
-52.1%
6M
-57.9%
YTD
-66.0%
1Y
-77.8%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$586.6M
P/E (trailing)–
P/E (forward)-4.2
52-week range2.84 – 14.58
Revenue growth (YoY, latest qtr)+173.5%
Dividend yield0.00%
Analyst consensusNone (5)
Mean price target$10.60 (+263%)
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•Piotroski F-score5/9
▼Altman Z-1.3 (distress)
▲Analyst target+263% (5 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.63 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.70 vs trailing $-1.47. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
-1316.8%
FCF margin
-1542.1%
Net margin
-1618.8%
Return on equity
-1437.3%
Return on invested capital
-382.9%
Net debt / EBITDA
–
Current ratio
2.6×
Interest cover
-2.9×
Cash conversion (OCF/NI)
–
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score -1.3 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$11
+263%
Analysts
5
None
Range
$6–$17
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $8.4M | $-182.6M | $-183.6M |
| 2024 | $0 | $-289.1M | $-200.4M |
| 2023 | $0 | $-101.7M | $-248.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
Next report: 2026-11-05 · during market · EPS est -0.25
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.28 | -0.30 | -6.4% |
| 2026-05-06 | -0.24 | -0.30 | -26.6% |
| 2026-02-26 | -0.25 | -0.07 | +71.2% |
| 2025-11-06 | -0.26 | -0.31 | -19.2% |
| 2025-08-07 | -0.20 | -0.81 | -311.9% |
| 2025-05-07 | -0.23 | 0.05 | +121.7% |
| 2025-02-27 | -0.20 | -0.40 | -101.7% |
| 2024-11-15 | -0.18 | -0.54 | -195.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $4.5M | +173.5% |
| 2026-03-31 | $4.1M | – |
| 2025-12-31 | $2.7M | – |
| 2025-09-30 | $2.4M | – |
| 2025-06-30 | $1.6M | – |
Analyst actions
Cantor Fitzgerald
PT $12
2026-08-07 · main
Overweight → OverweightPT $12
Cantor Fitzgerald
PT $14
2026-02-27 · main
Overweight → OverweightPT $14
TD Cowen
PT $9
2025-11-24 · down
Buy → HoldPT $9
Seaport Global
PT $23
2025-10-22 · init
→ BuyPT $23
Northland Capital Markets
PT $16
2025-08-27 · init
→ OutperformPT $16
Cantor Fitzgerald
PT $16
2025-08-08 · reit
Overweight → OverweightPT $16
Insider trades
Musa Fernando
$98.8K
Director · 2026-09-04
BUY$98.8K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
GlobeNewswire · Oct 01
PureCycle (PCT) Expands PureFive Use as Regulatory Tailwinds Meet Execution Risk
Insider Monkey · Sep 19
TIMEFLYS Advances Global Cosmetic Active Ingredient Platform with 39 International PCT Patent Assets
ACCESS Newswire · Sep 16
PureCycle (PCT) Turns Lab Promises Into Detergent Cap Reality
Insider Monkey · Sep 13
BALIMONT Details Global Expansion Strategy Built on 49 PCT Patent Assets
ACCESS Newswire · Sep 11
NVTIA Expands Global Nutraceutical Ingredient Platform With 53 PCT Patent Filings
TMX Newsfile · Aug 17
PureCycle (PCT) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13
IPL Schoeller & PureCycle Launch Off-the-Shelf Container Line, SnapPack Square EVO, Ahead of State Sustainability Mandates
GlobeNewswire · Aug 12
Stats refreshed 2026-10-19 19:02:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.